Vapreotide

Vapreotide can bind to somatostatin receptors (mainly sst2 and sst5 subtypes) with high affinity, mimicking the physiological effects of somatostatin and exerting inhibitory effects. It can inhibit the release of a variety of endocrine hormones, such as growth hormone, thyroid-stimulating hormone, insulin, glucagon, etc., and also has an inhibitory effect on gastrointestinal hormones such as gastrin and cholecystokinin, thereby regulating the body's metabolism and physiological functions. It can reduce the blood flow of internal organs, especially reduce the blood flow and pressure of the portal vein and its collateral circulation, which is of great significance in the treatment of portal hypertension and its complications. Vapreotide controls bleeding caused by rupture of gastroesophageal varices by reducing splanchnic blood flow and decreasing portal vein pressure. It is one of the commonly used hemostatic drugs in clinical practice and can be used as a first-line drug for emergency hemostasis. It is often used in combination with endoscopic treatment to improve the success rate of hemostasis and reduce the rebleeding rate. It can also be used in the treatment of acute pancreatitis. It can inhibit the secretion of pancreatic juice, reduce the autodigestion of the pancreas, relieve symptoms and reduce the incidence of complications. It can also be used to prevent postoperative complications of the pancreas, reduce the risk of postoperative complications such as pancreatic fistula, and promote the patient's postoperative recovery. For some somatostatin receptor-positive endocrine tumors, such as carcinoid tumors and islet cell tumors, vapreotide can inhibit tumor cells from secreting hormones and control tumor-related symptoms, such as flushing and diarrhea in carcinoid syndrome. To a certain extent, it may also inhibit the proliferation of tumor cells and delay tumor progression.